217 related articles for article (PubMed ID: 27799773)
21. Topoisomerase II alpha--a fundamental prognostic factor in breast carcinoma.
Hajduk M
Pol J Pathol; 2009; 60(2):67-75. PubMed ID: 19886180
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
[TBL] [Abstract][Full Text] [Related]
23. [Correlation of TOP2A gene expression and survival of breast cancer patients].
Meng H; Li WC; Wang LX; Li WB; Zhang L; Fan QX; Wang RL; Lu TY
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):363-6. PubMed ID: 21875466
[TBL] [Abstract][Full Text] [Related]
24. Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.
Huang H; Liu J; Meng Q; Niu G
Int J Clin Exp Pathol; 2015; 8(9):11537-42. PubMed ID: 26617887
[TBL] [Abstract][Full Text] [Related]
25. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer.
Sparano JA; Goldstein LJ; Davidson NE; Sledge GW; Gray R
Breast Cancer Res Treat; 2012 Jul; 134(2):751-7. PubMed ID: 22706628
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.
Heestand GM; Schwaederle M; Gatalica Z; Arguello D; Kurzrock R
Eur J Cancer; 2017 Sep; 83():80-87. PubMed ID: 28728050
[TBL] [Abstract][Full Text] [Related]
27. Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays.
Yang XQ; Chen C; Peng CW; Hou JX; Liu SP; Qi CB; Gong YP; Zhu XB; Pang DW; Li Y
Int J Nanomedicine; 2011; 6():2265-73. PubMed ID: 22072864
[TBL] [Abstract][Full Text] [Related]
28. Quantitative detection of the tumor-associated antigen large external antigen in colorectal cancer tissues and cells using quantum dot probe.
Wang S; Li W; Yuan D; Song J; Fang J
Int J Nanomedicine; 2016; 11():235-47. PubMed ID: 26834472
[TBL] [Abstract][Full Text] [Related]
29. Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer.
Nakagawa M; Bando Y; Nagao T; Morimoto M; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Sasa M; Tangoku A
Anticancer Res; 2011 Jun; 31(6):2389-93. PubMed ID: 21737670
[TBL] [Abstract][Full Text] [Related]
30. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
31. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
Almeida D; Gerhard R; Leitão D; Davilla C; Damasceno M; Schmitt F
Pathol Res Pract; 2014 Oct; 210(10):675-9. PubMed ID: 25042383
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.
Zaczek AJ; Markiewicz A; Seroczynska B; Skokowski J; Jaskiewicz J; Pienkowski T; Olszewski WP; Szade J; Rhone P; Welnicka-Jaskiewicz M; Jassem J
Oncologist; 2012; 17(10):1246-55. PubMed ID: 22871798
[TBL] [Abstract][Full Text] [Related]
33. Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways.
Yang Z; Liu Y; Shi C; Zhang Y; Lv R; Zhang R; Wang Q; Wang Y
Oncol Rep; 2017 Feb; 37(2):1011-1019. PubMed ID: 28075472
[TBL] [Abstract][Full Text] [Related]
34. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
36. Topoisomerase 2α status in invasive breast carcinoma - comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation.
Olszewski W; Pieńkowski T; Olszewski W; Mrozkowiak A; Bauer-Kosińska B; Piaścik A; Olszewska K; Wojnowska A; Michalski W
Pol J Pathol; 2014 Dec; 65(4):283-90. PubMed ID: 25693082
[TBL] [Abstract][Full Text] [Related]
37. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the predictive value of topoisomerase II alpha in patients with breast carcinoma.
Hajduk M; Olszewski WP; Smietana A
Pol J Pathol; 2009; 60(3):115-23. PubMed ID: 20069504
[TBL] [Abstract][Full Text] [Related]
39. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.
Karnes RJ; Cheville JC; Ida CM; Sebo TJ; Nair AA; Tang H; Munz JM; Kosari F; Vasmatzis G
Cancer Res; 2010 Nov; 70(22):8994-9002. PubMed ID: 21062978
[TBL] [Abstract][Full Text] [Related]
40. TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.
Moretti E; Desmedt C; Biagioni C; Regan MM; Oakman C; Larsimont D; Galardi F; Piccart-Gebhart M; Sotiriou C; Rimm DL; Di Leo A
Future Oncol; 2013 Oct; 9(10):1477-87. PubMed ID: 24106899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
